Revolution Medicines Inc – Ordinary Shares surged as positive oncology pipeline news drove bullish sentiment; stocks have been trading up by 41.35 percent
Key Takeaways
- Wall Street raised the bar on Revolution Medicines, with Jefferies boosting its RVMD price target to $140 and backing the RAS(ON) platform and RASolute 302 Phase 3 trial.
- Oppenheimer reiterated an Outperform on RVMD with a $150 target versus a recent price near $93, expecting a positive daraxonrasib pancreatic readout in 1H and an H2 regulatory filing.
- The company launched RASolute 303, a global Phase 3 trial testing daraxonrasib in first-line metastatic pancreatic cancer, alone and with chemotherapy, across all RAS genotypes.
- First patients have been dosed in another late-stage daraxonrasib trial, bringing RVMD’s total to four registrational studies in pancreatic and lung cancer.
- RVMD will showcase nine data sets at the 2026 AACR meeting, spanning zoldonrasib, multiple daraxonrasib datasets, a Phase 3 NSCLC design, and next‑generation RAS(ON) work.
Live Update At 16:03:15 EDT: On Monday, April 13, 2026 Revolution Medicines Inc – Ordinary Shares stock [NASDAQ: RVMD] is trending up by 41.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
RVMD has been trading like a biotech name with real momentum. In late March, Revolution Medicines stock was grinding in the low‑ to mid‑$90s. Over several sessions from 2026/03/19 through 2026/04/10, the daily closes mostly hugged the $92–$99 band, a classic consolidation after a prior move.
Then 2026/04/13 changed the script. RVMD opened near $132.26 and ripped to a high of $136.80, closing at $136.30. That is a huge gap up from the prior $96.43 close, signaling a sharp repricing of Revolution Medicines on the back of bullish daraxonrasib expectations and analyst targets.
Intraday, the 5‑minute chart shows a strong gap and volatile premarket action, followed by a trend‑day style grind where dips toward $133–$134 kept getting bought and the stock held above $130 all regular hours. For short‑term traders, that intraday pattern screams accumulation, not a one‑and‑done spike.
More Breaking News
- OWL Stock Jumps As Sale Talk And AI Deals Stir Momentum
- TNMG Stock Pulls Back As Traders Eye Debt And Support
- CMCSA Stock Grinds Higher As Restructuring Meets Earnings Beat
- NU Stock Plunges Nearly 20% As Volatility Spikes
Fundamentally, RVMD is a classic high‑burn, late‑stage biotech story. The company posted a quarterly net loss of about $364.9M and negative operating cash flow of roughly $274.2M, driven by $294.9M in research and development. Yet the balance sheet is thick: about $2.03B in cash and short‑term investments, current ratio 7.1, and modest long‑term debt around $142.2M. For traders, that combo—big cash, heavy R&D, no profits—means the chart will live and die on trial data and news flow, not traditional value metrics.
Why Traders Are Watching RVMD Now
RVMD is one of those biotech names where the story, the Street, and the chart just lined up. Revolution Medicines is pushing hard on its RAS(ON) platform, and daraxonrasib sits at the center of that push.
Jefferies fired the starting gun with a Buy rating and a price target jump to $140 from $88. That kind of move is not window dressing. It tells traders the firm believes the RASolute 302 Phase 3 trial in second‑line pancreatic cancer has a high chance of success at the first interim look. In biotech trading, “likely to succeed at interim” is code for “real binary catalyst on the horizon.”
Oppenheimer then backed that up, keeping an Outperform on RVMD and planting a $150 target while the stock was still around $93. The firm went further, saying the daraxonrasib Phase 3 in pancreatic cancer is expected to read out positively in the first half of the year, with a possible early stop and a regulatory filing in the second half. For active traders, that sets a clear catalyst calendar and explains why Revolution Medicines just broke out on heavy volume.
At the same time, the company is not betting on a single trial. RVMD has launched RASolute 303, a global Phase 3 in first‑line metastatic pancreatic ductal adenocarcinoma, running daraxonrasib both as monotherapy and with chemo, and enrolling regardless of RAS genotype. Add in the newly dosed global late‑stage trial of daraxonrasib (RMC‑6236) for first‑line pancreatic cancer and you get four ongoing registrational studies across pancreatic and non‑small cell lung cancer.
Layer on top the 2026 AACR catalyst: nine data sets, including Phase 1 for zoldonrasib in KRAS G12D NSCLC, multiple Phase 1/2 reads for daraxonrasib in first‑line pancreatic disease, a Phase 3 NSCLC design versus docetaxel, and preclinical next‑gen RAS(ON) work. RVMD is clearly trying to show that this is a platform, not a one‑drug story. That breadth is exactly what keeps traders glued to the tape.
There’s a counterweight. Multiple Form 4 filings show RVMD insiders selling shares in March 2026. The CEO, Mark A. Goldsmith, sold 12,871 shares for about $1.28M but still holds roughly 1.0M shares. The President of R&D, Stephen Michael Kelsey, sold 4,302 shares for about $428,000, retaining 295,398 shares. COO Margaret A. Horn sold 4,583 shares for about $455,919 and still owns 157,570 shares, while Chief Global Commercialization Officer Anthony Mancini sold 37,450 shares for about $3.58M and now holds 54,400 shares.
Those Form 4s, plus additional undisclosed‑detail insider changes, are worth tracking. But the remaining ownership suggests routine profit‑taking more than an exit. For short‑term RVMD trading, the heavier drivers remain analyst upgrades, Phase 3 progress, and AACR data.
Conclusion
RVMD is acting like a textbook late‑stage biotech momentum play. Revolution Medicines has stacked its deck with four registrational daraxonrasib trials across pancreatic and lung cancer, a dense 2026 AACR data slate, and two major firms—Jefferies and Oppenheimer—publicly signaling confidence with $140 and $150 price targets. The latest chart action, with RVMD blasting from the mid‑$90s to the mid‑$130s on strong demand, tells you traders are listening.
At the same time, the fundamentals remind everyone what kind of game this is. Revolution Medicines is burning hundreds of millions a year, with negative returns on equity and assets, and essentially no conventional earnings support at this stage. The cushion is its roughly $2.03B cash and investment pile and low leverage, which buys time to chase RAS‑driven cancers with its RAS(ON) platform.
Insider selling in March 2026 adds a note of caution, but the retained stakes signal that leadership still has skin in the game. For active traders studying RVMD, the real focus is timing and risk management around trial readouts, AACR presentations, and any surprise headlines. That means treating RVMD as part of a disciplined watchlist, not a one‑off gamble. As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” Applied here, that routine can help traders recognize how RVMD reacts around catalysts instead of chasing random spikes.
As Tim Sykes loves to say, “The market doesn’t care about your opinion, it cares about catalysts and price action.” For RVMD, the catalysts are lining up, and the price action just confirmed this is a ticker every catalyst‑driven trader should have on their screen—strictly for education and research, not as a substitute for doing your own homework and managing your own risk.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.